to confirm these data in an in-vitro model, which demonstrated that pDC are able to take up antigens derived from lysed tumor cells in a GzmB-dependent manner (Fig1).
In addition to the impact GzmB has on antigen uptake, the way it cleaves peptides can result in fragments that represent neo-antigens, allowing the establishment of increased immune responses towards such antigens [16, 17] . Thus, one reason for
The serine protease granzyme B (GzmB) is classically known to be an apoptogenic effector molecule produced by cytotoxic cells including NK cells and CD8+ T lymphocytes [1] . However,a series of further cell types are able to express GzmB, most of them in the absence of perforin.Below them are different antigen-presenting cells (APC) including B cells [2, 3] , monocyte derived dendritic cells [4, 5] and plasmacytoid dendritic cells [6, 7] . Meanwhile we know that GzmB contributes to a variety of APC-related functions. GzmB may therefore represent a promising novel target for the improvement of vaccination approaches based on the use of pDC and other dendritic cell types expressing GzmB.
Research in recent years has uncovered a variety of noncytotoxic roles of GzmB [8, 9] . Of note, the cytotoxic function of T cells and NK cells results from GzmB being secreted in the presence of the pore-forming protein perforin (Pfn). This allows GzmB to reach the cytosol of target cells after exocytosis, where it then activates apoptosis-inducing enzymes such as caspases, DNAses and BID [1] . In contrast, certain immune cells including plasmacytoid dendritic cells (pDC) [6, 10] and B cells [11, 12] can produce GzmB only, but not Pfn. GzmB secreted by these APC types therefore primarily encounters substrates with an extracellular or membrane-close localization such as extracellular proteins or membrane-bound receptors [8] . As a result, these cells develop a strong immune regulatory potential [6, 11, 12] based on GzmBdependent cleavage of the T cell receptor (TCR)-ζ-chain [9, 10, 13] . Consequently, loss of the TCR-ζ-chain directly limits the proliferative capacity and survival of effector T cells.
GzmB produced by APC however may not only play an important role for their interaction with T cells, but also for antigen processing. Recently, GzmB was shown to enhance both the uptake of antigens by release of eat-me signals on dying cells as well as their cross-presentation [14, 15] . Of note, we were able the development of autoimmune diseases may be the preferential degradation of antigens by GzmB, for example in the course of T cell-mediated attack of virus-infected cells. This suggests that antigens degraded by GzmB may be more immunogenic than antigens produced by other proteases. The reason why certain APC including pDC express GzmB may therefore be manifold. On the one hand, pDC-secreted GzmB may halt down unspecific T cell activation, while antigen loading and processing is ongoing. At the same time, GzmB may facilitate antigen uptake and processing into immunogenic fragments for cross-presentation (Fig. 2) . Overall, our data suggest that the dynamics of GzmB expression by pDC may strongly impact on their efficacy to induce antigen specific cellular immune responses. Further studies are necessary to elucidate, whether or not GzmB produced by APC may serve as a major target for the therapeutic manipulation of immune responses after vaccination.
